|
Ch1 Bakay L, Ballantine HT, Jr., Hueter TF, and Sosa D. 1956. Ultrasonically produced changes in the blood-brain barrier. AMA Arch Neurol Psychiatry 76:457-467. Ballantine HT, Jr., Bell E, and Manlapaz J. 1960. Progress and problems in the neurological applications of focused ultrasound. J Neurosurg 17:858-876. 10.3171/jns.1960.17.5.0858 Barnard JW, Fry WJ, Fry FJ, and Krumins RF. 1955. Effects of high intensity ultrasound on the central nervous system of the cat. J Comp Neurol 103:459-484. Dobrakowski PP, Machowska-Majchrzak AK, Labuz-Roszak B, Majchrzak KG, Kluczewska E, and Pierzchala KB. 2014. MR-guided focused ultrasound: a new generation treatment of Parkinson''s disease, essential tremor and neuropathic pain. Interv Neuroradiol 20:275-282. 10.15274/NRJ-2014-10033 10.15274/INR-2014-10033 Etame AB, Diaz RJ, Smith CA, Mainprize TG, Hynynen K, and Rutka JT. 2012. Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. Neurosurg Focus 32:E3. 10.3171/2011.10.FOCUS11252 Gabizon A, and Martin F. 1997. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 Suppl 4:15-21. Gabizon A, Shmeeda H, and Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 42:419-436. 10.2165/00003088-200342050-00002 Gabizon AA. 1992. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res 52:891-896. Gallay MN, Moser D, Rossi F, Pourtehrani P, Magara AE, Kowalski M, Arnold A, and Jeanmonod D. 2016. Incisionless transcranial MR-guided focused ultrasound in essential tremor: cerebellothalamic tractotomy. J Ther Ultrasound 4:5. 10.1186/s40349-016-0049-8 Hsiao YH, Kuo SJ, Tsai HD, Chou MC, and Yeh GP. 2016. Clinical Application of High-intensity Focused Ultrasound in Cancer Therapy. J Cancer 7:225-231. 10.7150/jca.13906 Hynynen K. 2008. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 60:1209-1217. 10.1016/j.addr.2008.03.010 Hynynen K, McDannold N, Vykhodtseva N, and Jolesz FA. 2001. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220:640-646. 10.1148/radiol.2202001804 Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, and Aghi MK. 2017. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg 126:191-200. 10.3171/2016.1.JNS151591 Jain KK. 2012. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond) 7:1225-1233. 10.2217/nnm.12.86 Kobus T, Vykhodtseva N, Pilatou M, Zhang Y, and McDannold N. 2016. Safety Validation of Repeated Blood-Brain Barrier Disruption Using Focused Ultrasound. Ultrasound Med Biol 42:481-492. 10.1016/j.ultrasmedbio.2015.10.009 La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, and Zamboni WC. 2012. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol 69:43-50. 10.1007/s00280-011-1664-2 Lesniak MS, Upadhyay U, Goodwin R, Tyler B, and Brem H. 2005. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25:3825-3831. Meairs S. 2015. Facilitation of Drug Transport across the Blood-Brain Barrier with Ultrasound and Microbubbles. Pharmaceutics 7:275-293. 10.3390/pharmaceutics7030275 Mitrasinovic S, Appelboom G, Detappe A, and Sander Connolly E, Jr. 2016. Focused ultrasound to transiently disrupt the blood brain barrier. J Clin Neurosci 28:187-189. 10.1016/j.jocn.2015.12.011 Pardridge WM. 2002. Drug and gene delivery to the brain: the vascular route. Neuron 36:555-558. Peschillo S, Caporlingua A, Diana F, Caporlingua F, and Delfini R. 2016. New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it. J Neurointerv Surg 8:1078-1082. 10.1136/neurintsurg-2015-012048 Pestalozzi BC, and Brignoli S. 2000. Trastuzumab in CSF. J Clin Oncol 18:2349-2351. 10.1200/JCO.2000.18.11.2349 Poon C, McMahon D, and Hynynen K. 2017. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound. Neuropharmacology 120:20-37. 10.1016/j.neuropharm.2016.02.014 U.S. Food and Drug Administration. 2016. FDA approves first MRI-guided focused ultrasound device to treat essential tremor. FDA news release https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm510595.htm von Holst H, Knochenhauer E, Blomgren H, Collins VP, Ehn L, Lindquist M, Noren G, and Peterson C. 1990. Uptake of adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas. Acta Neurochir (Wien) 104:13-16. Voulgaris S, Partheni M, Karamouzis M, Dimopoulos P, Papadakis N, and Kalofonos HP. 2002. Intratumoral doxorubicin in patients with malignant brain gliomas. Am J Clin Oncol 25:60-64. Vykhodtseva N, McDannold N, and Hynynen K. 2008. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 48:279-296. 10.1016/j.ultras.2008.04.004 Zaaroor M, Sinai A, Goldsher D, Eran A, Nassar M, and Schlesinger I. 2017. Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson''s disease and essential tremor cases. J Neurosurg:1-9. 10.3171/2016.10.JNS16758 Ch2 Beccaria K, Canney M, Goldwirt L, Fernandez C, Adam C, Piquet J, Autret G, Clement O, Lafon C, Chapelon JY, and Carpentier A. 2013. Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits. J Neurosurg 119:887-898. 10.3171/2013.5.JNS122374 Chen H, and Konofagou EE. 2014. The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure. J Cereb Blood Flow Metab 34:1197-1204. 10.1038/jcbfm.2014.71 Choi JJ, Selert K, Gao Z, Samiotaki G, Baseri B, and Konofagou EE. 2011. Noninvasive and localized blood-brain barrier disruption using focused ultrasound can be achieved at short pulse lengths and low pulse repetition frequencies. J Cereb Blood Flow Metab 31:725-737. 10.1038/jcbfm.2010.155 Chopra R, Vykhodtseva N, and Hynynen K. 2010. Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures. ACS Chem Neurosci 1:391-398. 10.1021/cn9000445 Doolittle ND, Miner ME, Hall WA, Siegal T, Jerome E, Osztie E, McAllister LD, Bubalo JS, Kraemer DF, Fortin D, Nixon R, Muldoon LL, and Neuwelt EA. 2000. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88:637-647. Etame AB, Diaz RJ, Smith CA, Mainprize TG, Hynynen K, and Rutka JT. 2012. Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. Neurosurg Focus 32:E3. 10.3171/2011.10.FOCUS11252 Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, and Neuwelt EA. 2010. Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery 66:48-58; discussion 58. 10.1227/01. NEU.0000363152.37594. F7 Horodyckid C, Canney M, Vignot A, Boisgard R, Drier A, Huberfeld G, Francois C, Prigent A, Santin MD, Adam C, Willer JC, Lafon C, Chapelon JY, and Carpentier A. 2016. Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model. J Neurosurg:1-11. 10.3171/2016.3.JNS151635 Howles GP, Bing KF, Qi Y, Rosenzweig SJ, Nightingale KR, and Johnson GA. 2010. Contrast-enhanced in vivo magnetic resonance microscopy of the mouse brain enabled by noninvasive opening of the blood-brain barrier with ultrasound. Magn Reson Med 64:995-1004. 10.1002/mrm.22411 Howles GP, Qi Y, and Johnson GA. 2010. Ultrasonic disruption of the blood-brain barrier enables in vivo functional mapping of the mouse barrel field cortex with manganese-enhanced MRI. Neuroimage 50:1464-1471. 10.1016/j.neuroimage.2010.01.050 Hynynen K. 2008. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 60:1209-1217. 10.1016/j.addr.2008.03.010 Hynynen K, McDannold N, Sheikov NA, Jolesz FA, and Vykhodtseva N. 2005. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 24:12-20. 10.1016/j.neuroimage.2004.06.046 Hynynen K, McDannold N, Vykhodtseva N, and Jolesz FA. 2001. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220:640-646. 10.1148/radiol.2202001804 Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, Jolesz FA, and Sheikov N. 2006. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 105:445-454. 10.3171/jns.2006.105.3.445 Jacobson O, Kiesewetter DO, and Chen X. 2016. Albumin-Binding Evans Blue Derivatives for Diagnostic Imaging and Production of Long-Acting Therapeutics. Bioconjug Chem. 10.1021/acs.bioconjchem.6b00487 Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, and Aghi MK. 2016. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg:1-10. 10.3171/2016.1.JNS151591 Kelly JM, Bradbury A, Martin DR, and Byrne ME. 2016. Emerging therapies for neuropathic lysosomal storage disorders. Prog Neurobiol. 10.1016/j.pneurobio.2016.10.002 Kim HJ, Kim YW, Choi SH, Cho BM, Bandu R, Ahn HS, and Kim KP. 2016. Triolein Emulsion Infusion Into the Carotid Artery Increases Brain Permeability to Anticancer Agents. Neurosurgery 78:726-733. 10.1227/NEU.0000000000001104 Kinoshita M, McDannold N, Jolesz FA, and Hynynen K. 2006. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 103:11719-11723. 10.1073/pnas.0604318103 Kobus T, Vykhodtseva N, Pilatou M, Zhang Y, and McDannold N. 2016. Safety Validation of Repeated Blood-Brain Barrier Disruption Using Focused Ultrasound. Ultrasound Med Biol 42:481-492. 10.1016/j.ultrasmedbio.2015.10.009 McDannold N, Arvanitis CD, Vykhodtseva N, and Livingstone MS. 2012. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 72:3652-3663. 10.1158/0008-5472.CAN-12-0128 McDannold N, Vykhodtseva N, and Hynynen K. 2008. Blood-brain barrier disruption induced by focused ultrasound and circulating preformed microbubbles appears to be characterized by the mechanical index. Ultrasound Med Biol 34:834-840. 10.1016/j.ultrasmedbio.2007.10.016 McDannold N, Vykhodtseva N, and Hynynen K. 2008. Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med Biol 34:930-937. 10.1016/j.ultrasmedbio.2007.11.009 McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, and Hynynen K. 2005. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol 31:1527-1537. 10.1016/j.ultrasmedbio.2005.07.010 Meairs S. 2015. Facilitation of Drug Transport across the Blood-Brain Barrier with Ultrasound and Microbubbles. Pharmaceutics 7:275-293. 10.3390/pharmaceutics7030275 Medel R, Monteith SJ, Elias WJ, Eames M, Snell J, Sheehan JP, Wintermark M, Jolesz FA, and Kassell NF. 2012. Magnetic resonance-guided focused ultrasound surgery: Part 2: A review of current and future applications. Neurosurgery 71:755-763. 10.1227/NEU.0b013e3182672ac9 Mitrasinovic S, Appelboom G, Detappe A, and Sander Connolly E, Jr. 2016. Focused ultrasound to transiently disrupt the blood brain barrier. J Clin Neurosci 28:187-189. 10.1016/j.jocn.2015.12.011 Morel DR, Schwieger I, Hohn L, Terrettaz J, Llull JB, Cornioley YA, and Schneider M. 2000. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging. Invest Radiol 35:80-85. Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, Buchan CG, and Hill SA. 1986. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgery 19:573-582. Pardridge WM. 2002. Drug and gene delivery to the brain: the vascular route. Neuron 36:555-558. Pestalozzi BC, and Brignoli S. 2000. Trastuzumab in CSF. J Clin Oncol 18:2349-2351. 10.1200/jco.2000.18.11.2349 Poon C, McMahon D, and Hynynen K. 2016. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound. Neuropharmacology. 10.1016/j.neuropharm.2016.02.014 Schad H, Haider M, and Brechtelsbauer H. 1987. [Determination of plasma volume with indocyanine green]. Anaesthesist 36:608-614. Schlachetzki F, Zhang Y, Boado RJ, and Pardridge WM. 2004. Gene therapy of the brain: the trans-vascular approach. Neurology 62:1275-1281. Sheikov N, McDannold N, Jolesz F, Zhang YZ, Tam K, and Hynynen K. 2006. Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. Ultrasound Med Biol 32:1399-1409. 10.1016/j.ultrasmedbio.2006.05.015 Sheikov N, McDannold N, Sharma S, and Hynynen K. 2008. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 34:1093-1104. 10.1016/j.ultrasmedbio.2007.12.015 Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, and Hynynen K. 2007. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121:901-907. 10.1002/ijc.22732 Vykhodtseva N, McDannold N, and Hynynen K. 2008. Progress and problems in the application of focused ultrasound for blood-brain barrier disruption. Ultrasonics 48:279-296. 10.1016/j.ultras.2008.04.004 Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M, Dana BW, and Neuwelt EA. 1995. Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37:17-27; discussion 27-18. Xie F, Boska MD, Lof J, Uberti MG, Tsutsui JM, and Porter TR. 2008. Effects of transcranial ultrasound and intravenous microbubbles on blood brain barrier permeability in a large animal model. Ultrasound Med Biol 34:2028-2034. 10.1016/j.ultrasmedbio.2008.05.004 Yang FY, Fu WM, Yang RS, Liou HC, Kang KH, and Lin WL. 2007. Quantitative evaluation of focused ultrasound with a contrast agent on blood-brain barrier disruption. Ultrasound Med Biol 33:1421-1427. 10.1016/j.ultrasmedbio.2007.04.006 Yao L, Song Q, Bai W, Zhang J, Miao D, Jiang M, Wang Y, Shen Z, Hu Q, Gu X, Huang M, Zheng G, Gao X, Hu B, Chen J, and Chen H. 2014. Facilitated brain delivery of poly (ethylene glycol)-poly (lactic acid) nanoparticles by microbubble-enhanced unfocused ultrasound. Biomaterials 35:3384-3395. 10.1016/j.biomaterials.2013.12.043 Yen LF, Wei VC, Kuo EY, and Lai TW. 2013. Distinct patterns of cerebral extravasation by Evans blue and sodium fluorescein in rats. PLoS One 8:e68595. 10.1371/journal.pone.0068595 Ch3 Beccaria K, Canney M, Goldwirt L, Fernandez C, Adam C, Piquet J, Autret G, Clement O, Lafon C, Chapelon JY, and Carpentier A. 2013. Opening of the blood-brain barrier with an unfocused ultrasound device in rabbits. J Neurosurg 119:887-898. 10.3171/2013.5.JNS122374 Belichenko PV, Dickson PI, Passage M, Jungles S, Mobley WC, and Kakkis ED. 2005. Penetration, diffusion, and uptake of recombinant human alpha-L-iduronidase after intraventricular injection into the rat brain. Mol Genet Metab 86:141-149. 10.1016/j.ymgme.2005.04.013 Chen A, Vogler C, McEntee M, Hanson S, Ellinwood NM, Jens J, Snella E, Passage M, Le S, Guerra C, and Dickson P. 2011. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase. APMIS 119:513-521. 10.1111/j.1600-0463.2011.02760.x Chen H, and Konofagou EE. 2014. The size of blood-brain barrier opening induced by focused ultrasound is dictated by the acoustic pressure. J Cereb Blood Flow Metab 34:1197-1204. 10.1038/jcbfm.2014.71 Choi JJ, Wang S, Tung YS, Morrison B, 3rd, and Konofagou EE. 2010. Molecules of various pharmacologically-relevant sizes can cross the ultrasound-induced blood-brain barrier opening in vivo. Ultrasound Med Biol 36:58-67. 10.1016/j.ultrasmedbio.2009.08.006 Chopra R, Vykhodtseva N, and Hynynen K. 2010. Influence of exposure time and pressure amplitude on blood-brain-barrier opening using transcranial ultrasound exposures. ACS Chem Neurosci 1:391-398. 10.1021/cn9000445 Chu PC, Chai WY, Hsieh HY, Wang JJ, Wey SP, Huang CY, Wei KC, and Liu HL. 2013. Pharmacodynamic analysis of magnetic resonance imaging-monitored focused ultrasound-induced blood-brain barrier opening for drug delivery to brain tumors. Biomed Res Int 2013:627496. 10.1155/2013/627496 Dickson P, McEntee M, Vogler C, Le S, Levy B, Peinovich M, Hanson S, Passage M, and Kakkis E. 2007. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 91:61-68. 10.1016/j.ymgme.2006.12.012 El-Amouri SS, Dai M, Han JF, Brady RO, and Pan D. 2014. Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase. Mol Ther 22:2028-2037. 10.1038/mt.2014.152 Etame AB, Diaz RJ, Smith CA, Mainprize TG, Hynynen K, and Rutka JT. 2012. Focused ultrasound disruption of the blood-brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. Neurosurg Focus 32:E3. 10.3171/2011.10.FOCUS11252 Fleischhack G, Jaehde U, and Bode U. 2005. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet 44:1-31. 10.2165/00003088-200544010-00001 Groothuis DR. 2000. The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2:45-59. Horodyckid C, Canney M, Vignot A, Boisgard R, Drier A, Huberfeld G, Francois C, Prigent A, Santin MD, Adam C, Willer JC, Lafon C, Chapelon JY, and Carpentier A. 2016. Safe long-term repeated disruption of the blood-brain barrier using an implantable ultrasound device: a multiparametric study in a primate model. J Neurosurg:1-11. 10.3171/2016.3.JNS151635 Howles GP, Bing KF, Qi Y, Rosenzweig SJ, Nightingale KR, and Johnson GA. 2010. Contrast-enhanced in vivo magnetic resonance microscopy of the mouse brain enabled by noninvasive opening of the blood-brain barrier with ultrasound. Magn Reson Med 64:995-1004. 10.1002/mrm.22411 Howles GP, Qi Y, and Johnson GA. 2010. Ultrasonic disruption of the blood-brain barrier enables in vivo functional mapping of the mouse barrel field cortex with manganese-enhanced MRI. Neuroimage 50:1464-1471. 10.1016/j.neuroimage.2010.01.050 Hynynen K. 2008. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 60:1209-1217. 10.1016/j.addr.2008.03.010 Hynynen K, McDannold N, Vykhodtseva N, Raymond S, Weissleder R, Jolesz FA, and Sheikov N. 2006. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 105:445-454. 10.3171/jns.2006.105.3.445 Jahangiri A, Chin AT, Flanigan PM, Chen R, Bankiewicz K, and Aghi MK. 2016. Convection-enhanced delivery in glioblastoma: a review of preclinical and clinical studies. J Neurosurg:1-10. 10.3171/2016.1.JNS151591 Jameson E, Jones S, and Remmington T. 2016. Enzyme replacement therapy with laronidase (Aldurazyme((R))) for treating mucopolysaccharidosis type I. Cochrane Database Syst Rev 4:CD009354. 10.1002/14651858.CD009354.pub4 Janson CG, Romanova LG, Leone P, Nan Z, Belur L, McIvor RS, and Low WC. 2014. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-alpha-L-Iduronidase for Hurler Disease. Neurosurgery 74:99-111. 10.1227/NEU.0000000000000157 Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, and Passage M. 2004. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 83:163-174. 10.1016/j.ymgme.2004.07.003 Kim HJ, Kim YW, Choi SH, Cho BM, Bandu R, Ahn HS, and Kim KP. 2016. Triolein Emulsion Infusion Into the Carotid Artery Increases Brain Permeability to Anticancer Agents. Neurosurgery 78:726-733. 10.1227/NEU.0000000000001104 Kinoshita M, McDannold N, Jolesz FA, and Hynynen K. 2006. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A 103:11719-11723. 10.1073/pnas.0604318103 Kobus T, Vykhodtseva N, Pilatou M, Zhang Y, and McDannold N. 2016. Safety Validation of Repeated Blood-Brain Barrier Disruption Using Focused Ultrasound. Ultrasound Med Biol 42:481-492. 10.1016/j.ultrasmedbio.2015.10.009 McDannold N, Arvanitis CD, Vykhodtseva N, and Livingstone MS. 2012. Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: safety and efficacy evaluation in rhesus macaques. Cancer Res 72:3652-3663. 10.1158/0008-5472.CAN-12-0128 McDannold N, Vykhodtseva N, and Hynynen K. 2008. Effects of acoustic parameters and ultrasound contrast agent dose on focused-ultrasound induced blood-brain barrier disruption. Ultrasound Med Biol 34:930-937. 10.1016/j.ultrasmedbio.2007.11.009 McDannold N, Vykhodtseva N, Raymond S, Jolesz FA, and Hynynen K. 2005. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol 31:1527-1537. 10.1016/j.ultrasmedbio.2005.07.010 Meairs S. 2015. Facilitation of Drug Transport across the Blood-Brain Barrier with Ultrasound and Microbubbles. Pharmaceutics 7:275-293. 10.3390/pharmaceutics7030275 Medel R, Monteith SJ, Elias WJ, Eames M, Snell J, Sheehan JP, Wintermark M, Jolesz FA, and Kassell NF. 2012. Magnetic resonance-guided focused ultrasound surgery: Part 2: A review of current and future applications. Neurosurgery 71:755-763. 10.1227/NEU.0b013e3182672ac9 Mitrasinovic S, Appelboom G, Detappe A, and Sander Connolly E, Jr. 2016. Focused ultrasound to transiently disrupt the blood brain barrier. J Clin Neurosci 28:187-189. 10.1016/j.jocn.2015.12.011 Ou L, Herzog T, Koniar BL, Gunther R, and Whitley CB. 2014. High-dose enzyme replacement therapy in murine Hurler syndrome. Mol Genet Metab 111:116-122. 10.1016/j.ymgme.2013.09.008 Poon C, McMahon D, and Hynynen K. 2016. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound. Neuropharmacology. 10.1016/j.neuropharm.2016.02.014 Rawson RA. 1943. The binding of T-1824 and structurally related diazo dyes by the plasma proteins. American Journal of Physiology 138:0708-0717. Raymond SB, Skoch J, Hynynen K, and Bacskai BJ. 2007. Multiphoton imaging of ultrasound/Optison mediated cerebrovascular effects in vivo. J Cereb Blood Flow Metab 27:393-403. 10.1038/sj.jcbfm.9600336 Sheikov N, McDannold N, Jolesz F, Zhang YZ, Tam K, and Hynynen K. 2006. Brain arterioles show more active vesicular transport of blood-borne tracer molecules than capillaries and venules after focused ultrasound-evoked opening of the blood-brain barrier. Ultrasound Med Biol 32:1399-1409. 10.1016/j.ultrasmedbio.2006.05.015 Sheikov N, McDannold N, Sharma S, and Hynynen K. 2008. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol 34:1093-1104. 10.1016/j.ultrasmedbio.2007.12.015 Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, and Hynynen K. 2007. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 121:901-907. 10.1002/ijc.22732 Vite CH, Wang P, Patel RT, Walton RM, Walkley SU, Sellers RS, Ellinwood NM, Cheng AS, White JT, O''Neill CA, and Haskins M. 2011. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations. Mol Genet Metab 103:268-274. 10.1016/j.ymgme.2011.03.011 Wolf DA, Lenander AW, Nan Z, Belur LR, Whitley CB, Gupta P, Low WC, and McIvor RS. 2011. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol Dis 43:123-133. 10.1016/j.nbd.2011.02.015 Wraith JE, and Jones S. 2014. Mucopolysaccharidosis type I. Pediatr Endocrinol Rev 12 Suppl 1:102-106. Xie F, Boska MD, Lof J, Uberti MG, Tsutsui JM, and Porter TR. 2008. Effects of transcranial ultrasound and intravenous microbubbles on blood brain barrier permeability in a large animal model. Ultrasound Med Biol 34:2028-2034. 10.1016/j.ultrasmedbio.2008.05.004 Yao L, Song Q, Bai W, Zhang J, Miao D, Jiang M, Wang Y, Shen Z, Hu Q, Gu X, Huang M, Zheng G, Gao X, Hu B, Chen J, and Chen H. 2014. Facilitated brain delivery of poly (ethylene glycol)-poly (lactic acid) nanoparticles by microbubble-enhanced unfocused ultrasound. Biomaterials 35:3384-3395. 10.1016/j.biomaterials.2013.12.043 Yen LF, Wei VC, Kuo EY, and Lai TW. 2013. Distinct patterns of cerebral extravasation by Evans blue and sodium fluorescein in rats. PLoS One 8:e68595. 10.1371/journal.pone.0068595 Ch4 Ashush H, Rozenszajn LA, Blass M, Barda-Saad M, Azimov D, Radnay J, Zipori D, and Rosenschein U. 2000. Apoptosis induction of human myeloid leukemic cells by ultrasound exposure. Cancer Res 60:1014-1020. Buldakov MA, Hassan MA, Jawaid P, Cherdyntseva NV, and Kondo T. 2015. Cellular effects of low-intensity pulsed ultrasound and X-irradiation in combination in two human leukaemia cell lines. Ultrason Sonochem 23:339-346. 10.1016/j.ultsonch.2014.08.018 Buldakov MA, Hassan MA, Zhao QL, Feril LB, Jr., Kudo N, Kondo T, Litvyakov NV, Bolshakov MA, Rostov VV, Cherdyntseva NV, and Riesz P. 2009. Influence of changing pulse repetition frequency on chemical and biological effects induced by low-intensity ultrasound in vitro. Ultrason Sonochem 16:392-397. 10.1016/j.ultsonch.2008.10.006 Feril LB, Jr., and Kondo T. 2004. Biological effects of low intensity ultrasound: the mechanism involved, and its implications on therapy and on biosafety of ultrasound. J Radiat Res 45:479-489. Feril LB, Jr., Kondo T, Cui ZG, Tabuchi Y, Zhao QL, Ando H, Misaki T, Yoshikawa H, and Umemura S. 2005. Apoptosis induced by the sonomechanical effects of low intensity pulsed ultrasound in a human leukemia cell line. Cancer Lett 221:145-152. 10.1016/j.canlet.2004.08.034 Feril LB, Jr., Kondo T, Zhao QL, and Ogawa R. 2002. Enhancement of hyperthermia-induced apoptosis by non-thermal effects of ultrasound. Cancer Lett 178:63-70. Frenkel V. 2008. Ultrasound mediated delivery of drugs and genes to solid tumors. Adv Drug Deliv Rev 60:1193-1208. 10.1016/j.addr.2008.03.007 Guzman HR, Nguyen DX, Khan S, and Prausnitz MR. 2001. Ultrasound-mediated disruption of cell membranes. II. Heterogeneous effects on cells. J Acoust Soc Am 110:597-606. Hahn GM, Braun J, and Har-Kedar I. 1975. Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A 72:937-940. Hassan MA, Buldakov MA, Ogawa R, Zhao QL, Furusawa Y, Kudo N, Kondo T, and Riesz P. 2010. Modulation control over ultrasound-mediated gene delivery: evaluating the importance of standing waves. J Control Release 141:70-76. 10.1016/j.jconrel.2009.08.020 Husseini GA, and Pitt WG. 2008. Micelles and nanoparticles for ultrasonic drug and gene delivery. Adv Drug Deliv Rev 60:1137-1152. 10.1016/j.addr.2008.03.008 Hynynen K. 2008. Ultrasound for drug and gene delivery to the brain. Adv Drug Deliv Rev 60:1209-1217. 10.1016/j.addr.2008.03.010 Jernberg A, Edgren MR, Lewensohn R, Wiksell H, and Brahme A. 2001. Cellular effects of high-intensity focused continuous wave ultrasound alone and in combination with X-rays. Int J Radiat Biol 77:127-135. Lejbkowicz F, and Salzberg S. 1997. Distinct sensitivity of normal and malignant cells to ultrasound in vitro. Environ Health Perspect 105 Suppl 6:1575-1578. Liu Y, Cho CW, Yan X, Henthorn TK, Lillehei KO, Cobb WN, and Ng KY. 2001. Ultrasound-Induced hyperthermia increases cellular uptake and cytotoxicity of P-glycoprotein substrates in multi-drug resistant cells. Pharm Res 18:1255-1261. Lizzi FL, and Ostromogilsky M. 1987. Analytical modelling of ultrasonically induced tissue heating. Ultrasound Med Biol 13:607-618. Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, and Smith QR. 2010. Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664-5678. 10.1158/1078-0432.CCR-10-1564 Loverock P, and ter Haar G. 1991. Synergism between hyperthermia, ultrasound and gamma irradiation. Ultrasound Med Biol 17:607-612. May JP, and Li SD. 2013. Hyperthermia-induced drug targeting. Expert Opin Drug Deliv 10:511-527. 10.1517/17425247.2013.758631 Mayer CR, and Bekeredjian R. 2008. Ultrasonic gene and drug delivery to the cardiovascular system. Adv Drug Deliv Rev 60:1177-1192. 10.1016/j.addr.2008.03.004 McDannold N, Vykhodtseva N, Jolesz FA, and Hynynen K. 2004. MRI investigation of the threshold for thermally induced blood-brain barrier disruption and brain tissue damage in the rabbit brain. Magn Reson Med 51:913-923. 10.1002/mrm.20060 Mitragotri S. 2005. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov 4:255-260. 10.1038/nrd1662 Muller OJ, Katus HA, and Bekeredjian R. 2007. Targeting the heart with gene therapy-optimized gene delivery methods. Cardiovasc Res 73:453-462. 10.1016/j.cardiores.2006.09.021 Nelson JL, Roeder BL, Carmen JC, Roloff F, and Pitt WG. 2002. Ultrasonically activated chemotherapeutic drug delivery in a rat model. Cancer Res 62:7280-7283. Ogilvie GK, Reynolds HA, Richardson BC, Badger CW, Goss SA, and Burdette EC. 1990. Performance of a multi-sector ultrasound hyperthermia applicator and control system: in vivo studies. Int J Hyperthermia 6:697-705. Pitt WG, Husseini GA, and Staples BJ. 2004. Ultrasonic drug delivery--a general review. Expert Opin Drug Deliv 1:37-56. 10.1517/17425247.1.1.37 Speed CA. 2001. Therapeutic ultrasound in soft tissue lesions. Rheumatology (Oxford) 40:1331-1336. Stringham SB, Viskovska MA, Richardson ES, Ohmine S, Husseini GA, Murray BK, and Pitt WG. 2009. Over-pressure suppresses ultrasonic-induced drug uptake. Ultrasound Med Biol 35:409-415. 10.1016/j.ultrasmedbio.2008.09.004 Suit HD, and Shwayder M. 1974. Hyperthermia: potential as an anti-tumor agent. Cancer 34:122-129. Tabuchi Y, Ando H, Takasaki I, Feril LB, Jr., Zhao QL, Ogawa R, Kudo N, Tachibana K, and Kondo T. 2007. Identification of genes responsive to low intensity pulsed ultrasound in a human leukemia cell line Molt-4. Cancer Lett 246:149-156. 10.1016/j.canlet.2006.02.011 Tang W, Liu Q, Wang X, Wang P, Cao B, Mi N, and Zhang J. 2008. Involvement of caspase 8 in apoptosis induced by ultrasound-activated hematoporphyrin in sarcoma 180 cells in vitro. J Ultrasound Med 27:645-656. Thanou M, and Gedroyc W. 2013. MRI-Guided Focused Ultrasound as a New Method of Drug Delivery. J Drug Deliv 2013:616197. 10.1155/2013/616197 Wang N, Tytell JD, and Ingber DE. 2009. Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus. Nat Rev Mol Cell Biol 10:75-82. 10.1038/nrm2594 Wu SK, Chiang CF, Hsu YH, Lin TH, Liou HC, Fu WM, and Lin WL. 2014. Short-time focused ultrasound hyperthermia enhances liposomal doxorubicin delivery and antitumor efficacy for brain metastasis of breast cancer. Int J Nanomedicine 9:4485-4494. 10.2147/IJN.S68347 Yoshida T, Kondo T, Ogawa R, Feril LB, Jr., Zhao QL, Watanabe A, and Tsukada K. 2008. Combination of doxorubicin and low-intensity ultrasound causes a synergistic enhancement in cell killing and an additive enhancement in apoptosis induction in human lymphoma U937 cells. Cancer Chemother Pharmacol 61:559-567. 10.1007/s00280-007-0503-y Zhong W, Sit WH, Wan JM, and Yu AC. 2011. Sonoporation induces apoptosis and cell cycle arrest in human promyelocytic leukemia cells. Ultrasound Med Biol 37:2149-2159. 10.1016/j.ultrasmedbio.2011.09.012 Ch5 Hynynen K, McDannold N, Vykhodtseva N, and Jolesz FA. 2001. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 220:640-646. 10.1148/radiol.2202001804 Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd LA, and Stupp R. 2004. Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res 10:3728-3736. 10.1158/1078-0432.CCR-03-0807 Patel M, McCully C, Godwin K, and Balis FM. 2003. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61:203-207.
|